Research programme: STAT3 transcription factor inhibitors - Singh Biotechnology

Drug Profile

Research programme: STAT3 transcription factor inhibitors - Singh Biotechnology

Alternative Names: SBT 100; SBT 101

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Singh Biotechnology
  • Class Antibodies; Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Aug 2016 Singh Biotechnology has patent protection for STAT3 transcription factor inhibitors (Singh Biotechnology website, August 2016)
  • 03 Jun 2016 Pharmacodynamic data from a preclinical study presented at 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top